We have ambitious long-term plans with our company: the number of products that can be developed based on the AMPs is large: basically any type of indication where bacterial infections play a role can be targeted.
Our strategy is to continuously develop products up-to and including clinical proof of concept, after which we partner them with the best partner to get the product towards patients worldwide. Our aim is to alleviate the burden of bacterial infections for patients worldwide, as well as for the global healthcare system including all its stakeholders.
Madam Therapeutics is now planning for the first clinical studies with these AMPs. This includes studies in which the AMPs are the active pharmaceutical ingredient (API) as antimicrobial component in a gel to treat bacterial infections in atopic dermatitis and in a nose spray/cream to treat nasal MRSA carriers. These two lead-products are furthest in development. In addition, we are also investing in continuous pre-clinical development of other products for other indications. These include anti-microbial products to combat chronic otitis media; products to prevent burn wound infections, as well as antimicrobial coatings for biomaterials.
Our products to treat bacterial infections in atopic dermatitis and nasal MRSA carriers are however our lead products and the first to move into clinical phase.